



Hernan Bazan, MD, DFSVS, FACS

CEO & Co-founder

November 2021

hbazan@ochsner.org; 504 444 2882 (cell)



US & GLOBAL UNMET NEED

Safe treatment for acute & chronic pain




Pain Prevalence

50 M+ U.S.



1 in 5 people

Worldwide, moderate
& severe chronic pain



Acetaminophen Liver toxicity

Leading cause of acute
liver failure
>60M U.S. consume
weekly basis



Opioid use disorder

>500,000 ER visits annually
Pain Rx medicine misuse



**93,000 opioid
overdose deaths**

2020

Rising opioid crisis in the U.S. highlights the urgency for a new selective compound with minimal toxicity


A novel non-opioid lacking liver toxicity will fill the large void for the safer treatment of acute & chronic pain

South Rampart
PHARMA | PAIN RELIEF
INNOVATION



OUR APPROACH: SAFE PAIN INNOVATION

SRP is an **acetaminophen analog** with *unique* mechanisms of action



Non-opioid pain relief

Lack liver toxicity

Fever reducer

Develop new small molecule drugs

Advantages

Low product cost

Increased patient accessibility

Absent liver toxicity, potent pain relief

COMPETITION

As a **novel pain asset**, SRP has a better safety profile than available pain medicines

COMPETITION

Opioids

Acetaminophen

Tylenol (J&J), Panadol (GSK)

Ibuprofen (NSAIDs)

Advil (Pfizer; GSK)

RISK

Abuse potential

Liver toxicity

Kidney toxicity,
stomach ulceration

SRP

Non-opioid

Lacks liver toxicity

No kidney toxicity

*SRP is a novel non-opioid which Mechanisms of Action explain its **lack of liver toxicity** and **pain relief***

COMPETITIVE LANDSCAPE

5 Market Segments


Where customers are today

Acetaminophen

NSAIDs

Opioids

Local anesthetics



COMPETITIVE LANDSCAPE

Adverse Effects

"Better pain medications with less side effects are needed"^{*†}

Acetaminophen & NSAIDs

Liver toxicity

Kidney injury

Gastrointestinal ulceration

Cardiotoxicity

Chronic pain

Acute pain

Diabetic neuropathy

Chemotherapy neuropathy

Gabapentinoids
(anticonvulsants)

Anxiety/Depression

Liver toxicity

Off-label use (no
FDA-approval)


South Rampart
PHARMA | PAIN RELIEF
INNOVATION



COMPETITIVE LANDSCAPE

Market Demand

Recent Deals & Valuations



SRP has plans to get to Ph 2 by Q4 2022



GLOBAL PAIN MARKET: 2017 - 2021

Pain Space Financing


**Global market (2020)
Pain management pharmaceuticals
was worth \$74B¹**

Projected  \$91.6B by 2027²

From 2017 – Sept. 2021:

- 178 series A, B or C financings completed for privately held companies within the chronic, acute and neuropathic pain sectors.
- \$1.38 B capital invested

Series A, B, and C Financings Completed in Pain Sector³



1- [Businesswire](#)

2- [Allied Market Research](#)



3- Pitchbook (includes US HQ companies, Series A, B or C in pain management pharma or devices)

MECHANISMS OF ACTION (MOA)


Lack of liver toxicity

SRP does **not** produce NAPQI
(toxic metabolite)

And, maintains *hepatic tight junctions*




Acetaminophen





SRP

Analgesia

AM404 is expressed in the periaqueductal gray area, the nociception (pain sensing) area of the brain



periaqueductal gray area



South Rampart
PHARMA | PAIN RELIEF
INNOVATION


IP STATUS

SRP put together aggressive IP strategy early to protect its IP around the world




INNOVATION PIPELINE

Broad therapeutic potential, addressing *multiple pain mechanisms* & *fever*



PATHWAY TO CLINICAL DEVELOPMENT



CO-FOUNDERS



Hernan A. Bazan MD, DFSVS, FACS
CEO & Co-Founder

Endowed John Ochsner Cardiovascular Innovation
Professor and Program Director
Section of Vascular/Endovascular Surgery

Dept. of Surgery
Ochsner Clinic



Nicolas G. Bazan MD, PhD
Scientific Co-Founder

Boyd Professor of Ophthalmology, Biochemistry
and Molecular Biology, and Neurology
Villere Chair Retinal Degenerative Diseases

Director, Neuroscience Center of Excellence
LSUHSC School Of Medicine



Lead asset discovery, synthesis and clinical development

**Coordinating 8 CROs' work leading to the FDA IND
safety, toxicology studies and large-scale cGMP pharmacological development**



TEAM



Hernan A. Bazan
MD, DFSVS, FACS
CEO, Co-Founder



Nicolas G. Bazan
MD, PhD
Scientific Co-Founder



Robert Dickey
MBA
CFO

SRP has assembled a team with large expertise to advance its lead compound through Phase 1 & 2 clinical trials



1

Shayne Gad, PhD DABT
Principal, [Gad Consulting Services](#)

> 45 years experience in FDA regulatory affairs and toxicology
Taken **135** new drugs to IND & clinical trials



Quotient
Sciences

3

[Quotient Sciences](#)

Phase 1 clinical trial; clinical pharmacology expertise



5

[Lubrizol Life Sciences](#)

Oral & IV formulation and manufacturing; Nano- & jet- milling



7

[Calvert Labs](#)

GLP toxicology studies

2

John Wetzel, PhD
Principal, [Wetzel Chemistry Consulting](#)

> 20 years in the Chemistry, Manufacturing & Controls (CMC)
Written CMC of **12** INDs, NDAs and post-approval filings

4

[Olon Ricerca Biosciences](#)

cGMP large-scale synthesis (> 9 Kg) of lead molecule

6

[Latitude Pharmaceuticals](#)

Large-scale Clinical Trial Material synthesis (Ph 1 & 2)

8

[Sannova Analytical](#)

Bioanalytical method development



**South Rampart
PHARMA** | PAIN RELIEF
INNOVATION




DISRUPTIVE APPROACH TO PAIN RELIEF

Safe Pain Innovation

**Strong product &
Unique mechanisms of
action**

Novel non-toxic & non-narcotic analgesics for the safer treatment safe acute, chronic, and neuropathic pain



**Blockbuster market
potential**

Number of Americans
suffering from acute or
chronic pain
>50M

The global pain market
is estimated to be over
\$74B

The U.S. market for
analgesics
\$32B

Worldwide
acetaminophen market
alone
\$1.5B

Broad IP

Exclusive license for use and marketing of SRP compounds

Experienced team

**Experienced in life science venture process; one prior IPO
Continuous NIH funding since early 1980s**

**Outside Validation &
Milestones**



**South Rampart
PHARMA** | PAIN RELIEF
INNOVATION





Thank you

hbazan@ochsner.org; 504 444 2882 (cell)